Eleven Biotherapeutics to Present at Biotech Showcase 2018
January 02 2018 - 4:30PM
Business Wire
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage
clinical oncology company advancing novel product candidates based
on its Targeted Protein Therapeutics (TPTs) platform, today
announced that Stephen Hurly, President and Chief Executive
Officer, will present a company overview at the 2018 Biotech
Showcase in San Francisco, CA on Tuesday, January 9, 2018 at 11:00
a.m. PST.
A live webcast can be accessed from the Investors & Media
section of Eleven's website, www.elevenbio.com. An archived replay
of the webcast will be available on the Company's website for 90
days after the conference.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage, clinical oncology
company advancing novel product candidates based upon the Company’s
targeted protein therapeutics (TPTs) platform. TPTs incorporate a
tumor-targeting antibody fragment and a protein cytotoxic payload
into a single protein molecule in order to achieve focused tumor
cell killing. Eleven’s lead TPT, Vicinium, is currently in a Phase
3 trial in non-muscle invasive bladder cancer, with topline
three-month data expected in mid-2018. The Company believes its TPT
approach offers significant advantages in treating cancer over
existing antibody drug conjugate technologies. The Company believes
its TPTs provide effective tumor targeting with broader cancer
cell-killing properties than are achievable with small molecule
payloads that require tumor cell proliferation and face multi-drug
resistant mechanisms. Additionally, the Company believes that its
TPT’s cancer cell-killing properties promote an anti-tumor immune
response that will potentially combine well with immune oncology
drugs such as checkpoint inhibitors. For more information, please
refer to the Company’s website at www.elevenbio.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180102005621/en/
Stern Investor Relations, Inc.Michael Schaffzin,
212-362-1200michael@sternir.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024